Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Pacira BioSciences Inc
PCRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$36.34
0.01
0.03%
Últ. Act.: Oct 22, 4:00 PM
$36.34
0.01
0.03%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Pacira BioSciences Financials
Pacira BioSciences (PCRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone
Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Iran tensions. PepsiCo and Pacira shares rose.
Avi Kapoor
PRO
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
Benzinga Newsdesk
PRO
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of $0.74 per share from
Benzinga Newsdesk
PRO
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est
Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to $770Non-GAAP gross
Benzinga Newsdesk
PRO
Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.56 by 7.14 percent. This is a 3.23 percent decrease over earnings of $0.62 per share from
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
